Young Hoon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young Hoon Kim has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Sung Shin
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
12 shared publications - Hyunwook Kwon
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
11 shared publications - Youngmin Ko
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
8 shared publications - Joo Hee Jung
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7 shared publications - Chung Hee Baek
Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
6 shared publications - Hye Eun Kwon
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 16 May 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 39 (4) , 317-325
Bowel complications requiring surgical intervention in kidney transplant recipients: a retrospective study of clinical characteristics and risk factors
Jin-Myung Kim, Tuan Thanh Nguyen, Hye Eun Kwon, Youngmin Ko, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Sung Shin. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.24.0071
- 16 May 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 39 (4) , 317-325
Open AccessBowel complications requiring surgical intervention in kidney transplant recipients: a retrospective study of clinical characteristics and risk factors
Jin-Myung Kim, Tuan Thanh Nguyen, Hye Eun Kwon, Youngmin Ko, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Sung Shin. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.24.0071
- 29 April 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (6) , 1589-1597
Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients—propensity score-matched analysis
Background Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARBs) can cause acute kidney injury under dehydratation or in hemodynamically unstable conditions. Regarding kidney transplantation (KT), the risk of using ACEi/ARBs before surgery is not well established. Therefore, we evaluated the clinical outcomes to determine the effect of preoperative use of ACEi/ARBs on KT. Methods We retrospectively collected 1187 patients who received living-donor KT between January 2017 and December 2021. We conducted a propensity score-matched analysis between the ACEi/ARB(+) and ACEi/ARB(–) groups and evaluated the effects of ACEi/ARBs on delayed graft function, post-KT renal function, hyperkalemia events, rejection, and graft survival. Results The ACEi/ARB(+) group showed a similar incidence of delayed graft function as the ACEi/ARB(–) group (1.8% vs. 1.0%, P = 0.362). The risk of delayed graft function was not upregulated in the ACEi/ARB(+) group after propensity score-matching (odds ratio: 0.50, 95% confidence interval (CI) 0.13–2.00). Postoperative creatinine levels and the slope of creatinine levels after KT also were not significantly different between the two groups (creatinine slope from POD#0 to POD#7: – 0.73 ± 0.35 vs. – 0.75 ± 0.32 mg/dL/day, P = 0.464). Hyperkalemia did not occur more often in the ACEi/ARB(+) group than in the ACEi/ARB(–) group during perioperative days. Rejection-free survival (P = 0.920) and graft survival (P = 0.621) were not significantly different between the two groups. Conclusions In KT, the preoperative use of ACEi/ARBs did not significantly affect clinical outcomes including delayed graft function, postoperative renal function, hyperkalemia events, incidence of rejection, and graft survival rates compared to the patients who did not receive ACEi/ARBs. Graphical abstract
- 29 April 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (6) , 1589-1597
Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients—propensity score-matched analysis
Background Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARBs) can cause acute kidney injury under dehydratation or in hemodynamically unstable conditions. Regarding kidney transplantation (KT), the risk of using ACEi/ARBs before surgery is not well established. Therefore, we evaluated the clinical outcomes to determine the effect of preoperative use of ACEi/ARBs on KT. Methods We retrospectively collected 1187 patients who received living-donor KT between January 2017 and December 2021. We conducted a propensity score-matched analysis between the ACEi/ARB(+) and ACEi/ARB(–) groups and evaluated the effects of ACEi/ARBs on delayed graft function, post-KT renal function, hyperkalemia events, rejection, and graft survival. Results The ACEi/ARB(+) group showed a similar incidence of delayed graft function as the ACEi/ARB(–) group (1.8% vs. 1.0%, P = 0.362). The risk of delayed graft function was not upregulated in the ACEi/ARB(+) group after propensity score-matching (odds ratio: 0.50, 95% confidence interval (CI) 0.13–2.00). Postoperative creatinine levels and the slope of creatinine levels after KT also were not significantly different between the two groups (creatinine slope from POD#0 to POD#7: – 0.73 ± 0.35 vs. – 0.75 ± 0.32 mg/dL/day, P = 0.464). Hyperkalemia did not occur more often in the ACEi/ARB(+) group than in the ACEi/ARB(–) group during perioperative days. Rejection-free survival (P = 0.920) and graft survival (P = 0.621) were not significantly different between the two groups. Conclusions In KT, the preoperative use of ACEi/ARBs did not significantly affect clinical outcomes including delayed graft function, postoperative renal function, hyperkalemia events, incidence of rejection, and graft survival rates compared to the patients who did not receive ACEi/ARBs. Graphical abstract
- Open Access
- 12 January 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (1) , 86-98
Association of metformin with cardiovascular and graft outcomes in kidney transplant recipients with posttransplantation diabetes mellitus
Posttransplantation diabetes mellitus (PTDM) is a crucial problem after kidney transplantation. We aimed to determine whether metformin affects cardiovascular and graft outcomes in patients with PTDM. This retrospective cohort study included 1,663 kidney transplant recipients without preexisting diabetes mellitus. The patients were divided into metformin and non-metformin groups, with matched propensity scores. We also estimated metformin's effect on percutaneous coronary intervention (PCI), major adverse cardiovascular events (MACEs), acute rejection, and graft failure. Of 634 recipients with PTDM, 406 recipients were treated with metformin. The incidence of PCI was 2.4% and 7.1% in the metformin and non-metformin groups, respectively (p = 0.04). The metformin group exhibited a lower risk of PCI in Cox regression analyses (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.10-0.77; p = 0.014), especially in subgroups with male sex, age over 49 years (median), long-term metformin use (mean of ≥1,729 days), and simultaneous tacrolimus administration. Long-term metformin use was also associated with lower incidence of MACEs (HR, 0.09; 95% CI, 0.01-0.67; p = 0.02). Incidence of graft failure was 9.9% and 17.0% in the metformin and non-metformin groups, respectively (p = 0.046). Both long-term use and higher dose of metformin, as well as tacrolimus administration with metformin, were associated with a lower risk of graft failure (HR, 0.29; 95% CI, 0.11-0.75; p = 0.01; HR, 0.39; 95% CI, 0.18-0.85; p = 0.02; and HR, 0.39; 95% CI, 0.19-0.79; p = 0.009, respectively). Metformin use is associated with a decreased risk of developing coronary artery disease and better graft outcomes in PTDM.
- 12 January 2024
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (1) , 86-98
Open AccessAssociation of metformin with cardiovascular and graft outcomes in kidney transplant recipients with posttransplantation diabetes mellitus
Posttransplantation diabetes mellitus (PTDM) is a crucial problem after kidney transplantation. We aimed to determine whether metformin affects cardiovascular and graft outcomes in patients with PTDM. This retrospective cohort study included 1,663 kidney transplant recipients without preexisting diabetes mellitus. The patients were divided into metformin and non-metformin groups, with matched propensity scores. We also estimated metformin's effect on percutaneous coronary intervention (PCI), major adverse cardiovascular events (MACEs), acute rejection, and graft failure. Of 634 recipients with PTDM, 406 recipients were treated with metformin. The incidence of PCI was 2.4% and 7.1% in the metformin and non-metformin groups, respectively (p = 0.04). The metformin group exhibited a lower risk of PCI in Cox regression analyses (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.10-0.77; p = 0.014), especially in subgroups with male sex, age over 49 years (median), long-term metformin use (mean of ≥1,729 days), and simultaneous tacrolimus administration. Long-term metformin use was also associated with lower incidence of MACEs (HR, 0.09; 95% CI, 0.01-0.67; p = 0.02). Incidence of graft failure was 9.9% and 17.0% in the metformin and non-metformin groups, respectively (p = 0.046). Both long-term use and higher dose of metformin, as well as tacrolimus administration with metformin, were associated with a lower risk of graft failure (HR, 0.29; 95% CI, 0.11-0.75; p = 0.01; HR, 0.39; 95% CI, 0.18-0.85; p = 0.02; and HR, 0.39; 95% CI, 0.19-0.79; p = 0.009, respectively). Metformin use is associated with a decreased risk of developing coronary artery disease and better graft outcomes in PTDM.
- Open Access
- 27 December 2023
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e942763-e942763-11
Immunoprotective Effect of Liver Allograft on Patients with Combined Liver and Kidney Transplantation
BACKGROUND Simultaneous liver-kidney transplantation (SLKT) and kidney transplantation (KT) after liver transplantation (LT) provide potential treatment options for patients with end-stage liver and kidney disease. There is increasing attention being given to liver-kidney transplantation (LTKT), particularly regarding the immune-protective effects of the liver graft. This retrospective, single-center, observational study aimed to evaluate the clinical outcomes of KT in LTKT patients - either SLKT or KT after LT (KALT) - compared to KT alone (KTA). MATERIAL AND METHODS We included patients who underwent KT between January 2005 and December 2020, comprising a total of 4312 patients divided into KTA (n=4268) and LTKT (n=44) groups. The LTKT group included 11 SLKT and 33 KALT patients. To balance the difference in sample sizes between the 2 groups, we performed 3: 1 propensity score matching (PSM). RESULTS There was no significant difference in graft survival between the groups. However, the LTKT group exhibited significantly superior rejection-free survival compared to the KTA group (P.
- 27 December 2023
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e942763-e942763-11
Open AccessImmunoprotective Effect of Liver Allograft on Patients with Combined Liver and Kidney Transplantation
BACKGROUND Simultaneous liver-kidney transplantation (SLKT) and kidney transplantation (KT) after liver transplantation (LT) provide potential treatment options for patients with end-stage liver and kidney disease. There is increasing attention being given to liver-kidney transplantation (LTKT), particularly regarding the immune-protective effects of the liver graft. This retrospective, single-center, observational study aimed to evaluate the clinical outcomes of KT in LTKT patients - either SLKT or KT after LT (KALT) - compared to KT alone (KTA). MATERIAL AND METHODS We included patients who underwent KT between January 2005 and December 2020, comprising a total of 4312 patients divided into KTA (n=4268) and LTKT (n=44) groups. The LTKT group included 11 SLKT and 33 KALT patients. To balance the difference in sample sizes between the 2 groups, we performed 3: 1 propensity score matching (PSM). RESULTS There was no significant difference in graft survival between the groups. However, the LTKT group exhibited significantly superior rejection-free survival compared to the KTA group (P.
- Open Access
- 11 August 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (3) , 210-215
Robot-assisted kidney transplantation in a morbidly obese patient with incisional hernia reconstruction and abdominoplasty: a case report
Jin-Myung Kim, Hye Eun Kwon, Youngmin Ko, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Eun Key Kim, Sung Shin. Korean J Transplant 2023;37:210-5. https://doi.org/10.4285/kjt.23.0021
- 11 August 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (3) , 210-215
Open AccessRobot-assisted kidney transplantation in a morbidly obese patient with incisional hernia reconstruction and abdominoplasty: a case report
Jin-Myung Kim, Hye Eun Kwon, Youngmin Ko, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Eun Key Kim, Sung Shin. Korean J Transplant 2023;37:210-5. https://doi.org/10.4285/kjt.23.0021
- Open Access
- 30 June 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (2) , 135-140
Transplant-associated Kaposi’s sarcoma in a kidney allograft: a case report
Jae Jun Lee, Jin-Myung Kim, Youngmin Ko, Hye Eun Kwon, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Sung Shin. Korean J Transplant 2023;37:135-40. https://doi.org/10.4285/kjt.23.0001
- 30 June 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (2) , 135-140
Open AccessTransplant-associated Kaposi’s sarcoma in a kidney allograft: a case report
Jae Jun Lee, Jin-Myung Kim, Youngmin Ko, Hye Eun Kwon, Joo Hee Jung, Hyunwook Kwon, Young Hoon Kim, Sung Shin. Korean J Transplant 2023;37:135-40. https://doi.org/10.4285/kjt.23.0001
- Open Access
- 21 February 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (1) , 49-56
Different antibody responses between liver and kidney transplant recipients elicited by third doses of COVID-19 mRNA vaccines
So Yun Lim, Young-In Yoon, Ji Yeun Kim, Eunyoung Tak, Hyunwook Kwon, Sung Shin, Young Hoon Kim, Gi-Won Song, Sung-Han Kim, Sung-Gyu Lee. Korean J Transplant -0001;0:. https://doi.org/10.4285/kjt.22.0056
- 21 February 2023
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 37 (1) , 49-56
Open AccessDifferent antibody responses between liver and kidney transplant recipients elicited by third doses of COVID-19 mRNA vaccines
So Yun Lim, Young-In Yoon, Ji Yeun Kim, Eunyoung Tak, Hyunwook Kwon, Sung Shin, Young Hoon Kim, Gi-Won Song, Sung-Han Kim, Sung-Gyu Lee. Korean J Transplant -0001;0:. https://doi.org/10.4285/kjt.22.0056
- Open Access
- 22 February 2022
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 41 (4) , 473-481
Parathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study
Background: Hyperparathyroidism is common in patients with chronic kidney disease with reduced renal function and has been observed after kidney transplantation. The optimal treatment for cases in which hyperparathyroidism persists after kidney transplantation has not been determined. Methods: This retrospective study included 83 patients with tertiary hyperparathyroidism who underwent kidney transplantation between 2000 and 2018 at a single tertiary center in Korea. Sixty-four patients underwent parathyroidectomy and 19 patients were treated with cinacalcet following renal transplantation. Biochemical parameters and clinical outcomes were compared between the two groups. Results: Serum calcium and parathyroid hormone (PTH) levels improved in both the parathyroidectomy and cinacalcet groups. One year after treatment, parathyroidectomy resulted in a lower mean serum calcium level than cinacalcet (9.7 ± 0.7 mg/dL vs. 10.5 ± 0.7 mg/dL, p = 0.001). Regarding serum PTH, the parathyroidectomy group showed a significantly lower PTH level than the cinacalcet group at 6 months (129.1 ± 80.3 pg/mL vs. 219.2 ± 92.5 pg/mL, p = 0.002) and 1 year (118.8 ± 75.5 pg/mL vs. 250.6 ± 94.5 pg/ mL, p < 0.001). There was no statistically significant difference in the incidence of kidney transplant rejection, graft failure, cardiovascular events, fracture risk, or bone mineral density changes between the two groups. Conclusion: Parathyroidectomy appears to reduce PTH and calcium levels effectively in tertiary hyperparathyroidism. However, creatinine level and allograft rejection should be monitored closely.
- 22 February 2022
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 41 (4) , 473-481
Open AccessParathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study
Background: Hyperparathyroidism is common in patients with chronic kidney disease with reduced renal function and has been observed after kidney transplantation. The optimal treatment for cases in which hyperparathyroidism persists after kidney transplantation has not been determined. Methods: This retrospective study included 83 patients with tertiary hyperparathyroidism who underwent kidney transplantation between 2000 and 2018 at a single tertiary center in Korea. Sixty-four patients underwent parathyroidectomy and 19 patients were treated with cinacalcet following renal transplantation. Biochemical parameters and clinical outcomes were compared between the two groups. Results: Serum calcium and parathyroid hormone (PTH) levels improved in both the parathyroidectomy and cinacalcet groups. One year after treatment, parathyroidectomy resulted in a lower mean serum calcium level than cinacalcet (9.7 ± 0.7 mg/dL vs. 10.5 ± 0.7 mg/dL, p = 0.001). Regarding serum PTH, the parathyroidectomy group showed a significantly lower PTH level than the cinacalcet group at 6 months (129.1 ± 80.3 pg/mL vs. 219.2 ± 92.5 pg/mL, p = 0.002) and 1 year (118.8 ± 75.5 pg/mL vs. 250.6 ± 94.5 pg/ mL, p < 0.001). There was no statistically significant difference in the incidence of kidney transplant rejection, graft failure, cardiovascular events, fracture risk, or bone mineral density changes between the two groups. Conclusion: Parathyroidectomy appears to reduce PTH and calcium levels effectively in tertiary hyperparathyroidism. However, creatinine level and allograft rejection should be monitored closely.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (1) , e4
Kidney Transplantation From Deceased Donors With Bloodstream Infection: A Multicenter Retrospective Study
Mo H, et al. J Korean Med Sci. 2021 Nov;37(1):e4. https://doi.org/10.3346/jkms.2022.37.e4
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (1) , e4
Open AccessKidney Transplantation From Deceased Donors With Bloodstream Infection: A Multicenter Retrospective Study
Mo H, et al. J Korean Med Sci. 2021 Nov;37(1):e4. https://doi.org/10.3346/jkms.2022.37.e4
- Open Access
- 1 January 2022
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 102 (1) , 55-63
Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment
Lee H, et al. Ann Surg Treat Res. 2022 Jan;102(1):55-63. https://doi.org/10.4174/astr.2022.102.1.55
- 1 January 2022
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 102 (1) , 55-63
Open AccessHepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment
Lee H, et al. Ann Surg Treat Res. 2022 Jan;102(1):55-63. https://doi.org/10.4174/astr.2022.102.1.55